Your blog has been created!
http://www.biomsmedical.com/Company Profile
BioMS Medical is a Canadian biotech company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of Multiple Sclerosis (MS).
BioMS Medical has obtained an exclusive worldwide license to a proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The technology, dirucotide (formally named MBP8298), is a synthetic myelin basic protein peptide comprised of 17 amino acids which is intravenously injected (every six months) into MS patients as a therapeutic treatment.
BioMS is currently conducting late-stage clinical trials and one open-label trial for dirucotide in secondary progressive MS:
